Bronchoalveolar lavage fluid analysis in patients with checkpoint inhibitor pneumonitis.
Bronchoalveolar lavage fluid
Checkpoint inhibitor pneumonitis
Immune-related adverse event
Lymphocyte subset analysis
Journal
Cancer immunology, immunotherapy : CII
ISSN: 1432-0851
Titre abrégé: Cancer Immunol Immunother
Pays: Germany
ID NLM: 8605732
Informations de publication
Date de publication:
13 Sep 2024
13 Sep 2024
Historique:
received:
07
06
2024
accepted:
06
09
2024
medline:
14
9
2024
pubmed:
14
9
2024
entrez:
13
9
2024
Statut:
epublish
Résumé
Checkpoint inhibitor pneumonitis (CIP) is a relatively uncommon but potentially life-threatening immune-related adverse event (irAE). Lung biopsies have not been commonly performed for CIP patients. Bronchoalveolar lavage fluid (BALF) analysis is a useful diagnostic approach for interstitial lung disease. However, BALF features were inconsistent across different studies. We retrospectively reviewed the medical records of 154 patients with pathologically confirmed malignancies and suffering from CIPs between July 2018 and December 2022. Patients who had bronchoalveolar lavage (BAL) data available were enrolled in our study. Patient clinical, laboratory, radiological and follow-up data were reviewed and analyzed. The BALF differential cell count and lymphocyte subset analysis were performed for 42 CIP patients. There were 32 males (76.2%). The mean age at diagnosis of CIP was 62.0 ± 10.4 (range: 31-78) years. The median time to onset of CIP was 98.5 days after the start of immunotherapy. There were 18 patients (42.9%) with low-grade CIPs and 24 patients (57.1%) with high-grade CIPs. The mean lymphocyte percentage was 36.7 ± 22.5%. There were 34 (81%) CIP patients with a lymphocytic cellular pattern. The median ratio of CD3 The CD3
Sections du résumé
BACKGROUND
BACKGROUND
Checkpoint inhibitor pneumonitis (CIP) is a relatively uncommon but potentially life-threatening immune-related adverse event (irAE). Lung biopsies have not been commonly performed for CIP patients. Bronchoalveolar lavage fluid (BALF) analysis is a useful diagnostic approach for interstitial lung disease. However, BALF features were inconsistent across different studies.
METHODS
METHODS
We retrospectively reviewed the medical records of 154 patients with pathologically confirmed malignancies and suffering from CIPs between July 2018 and December 2022. Patients who had bronchoalveolar lavage (BAL) data available were enrolled in our study. Patient clinical, laboratory, radiological and follow-up data were reviewed and analyzed.
RESULTS
RESULTS
The BALF differential cell count and lymphocyte subset analysis were performed for 42 CIP patients. There were 32 males (76.2%). The mean age at diagnosis of CIP was 62.0 ± 10.4 (range: 31-78) years. The median time to onset of CIP was 98.5 days after the start of immunotherapy. There were 18 patients (42.9%) with low-grade CIPs and 24 patients (57.1%) with high-grade CIPs. The mean lymphocyte percentage was 36.7 ± 22.5%. There were 34 (81%) CIP patients with a lymphocytic cellular pattern. The median ratio of CD3
CONCLUSIONS
CONCLUSIONS
The CD3
Identifiants
pubmed: 39271538
doi: 10.1007/s00262-024-03834-y
pii: 10.1007/s00262-024-03834-y
doi:
Substances chimiques
Immune Checkpoint Inhibitors
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
235Subventions
Organisme : National High Level Hospital Clinical Research Funding
ID : 2022-PUMCH-C-069
Organisme : National High Level Hospital Clinical Research Funding
ID : 2022-PUMCH-A-009
Organisme : National High Level Hospital Clinical Research Funding
ID : 2022-PUMCH-C-054
Informations de copyright
© 2024. The Author(s).
Références
Postow MA, Sidlow R, Hellmann MD (2018) Immune-related adverse events associated with immune checkpoint blockade. N Engl J Med 378(2):158–168. https://doi.org/10.1056/NEJMra1703481
doi: 10.1056/NEJMra1703481
pubmed: 29320654
Ramos-Casals M, Brahmer JR, Callahan MK, Flores-Chavez A, Keegan N, Khamashta MA, Lambotte O, Mariette X, Prat A, Suarez-Almazor ME (2020) Immune-related adverse events of checkpoint inhibitors. Nat Rev Dis Primers 6(1):38. https://doi.org/10.1038/s41572-020-0160-6
doi: 10.1038/s41572-020-0160-6
pubmed: 32382051
pmcid: 9728094
Rashdan S, Minna JD, Gerber DE (2018) Diagnosis and management of pulmonary toxicity associated with cancer immunotherapy. Lancet Respir Med 6(6):472–478. https://doi.org/10.1016/S2213-2600(18)30172-3
doi: 10.1016/S2213-2600(18)30172-3
pubmed: 29856320
pmcid: 7341891
Nguyen LS, Bretagne M, Arrondeau J, Zahr N, Ederhy S, Abbar B, Pinna B, Allenbach Y, Mira JP, Moslehi J et al (2022) Reversal of immune-checkpoint inhibitor fulminant myocarditis using personalized-dose-adjusted abatacept and ruxolitinib: proof of concept. J Immunother Cancer 10(4):e004699. https://doi.org/10.1136/jitc-2022-004699
doi: 10.1136/jitc-2022-004699
pubmed: 35383117
pmcid: 8984056
Bukhari S, Henick BS, Winchester RJ, Lerrer S, Adam K, Gartshteyn Y, Maniar R, Lin Z, Khodadadi-Jamayran A, Tsirigos A et al (2023) Single-cell RNA sequencing reveals distinct T cell populations in immune-related adverse events of checkpoint inhibitors. Cell Rep Med 4(1):100868. https://doi.org/10.1016/j.xcrm.2022.100868
doi: 10.1016/j.xcrm.2022.100868
pubmed: 36513074
Takahashi Y, Nagaya T, Iwaya Y, Okamura T, Hirayama A, Iwaya M, Uehara T, Umemura T (2023) CD8(+) lymphocyte infiltration is a specific feature of colitis induced by immune checkpoint inhibitors. Dig Dis Sci 68(2):451–459. https://doi.org/10.1007/s10620-022-07598-2
doi: 10.1007/s10620-022-07598-2
pubmed: 35748996
Hone Lopez S, Kats-Ugurlu G, Renken RJ, Buikema HJ, de Groot MR, Visschedijk MC, Dijkstra G, Jalving M, de Haan JJ (2021) Immune checkpoint inhibitor treatment induces colitis with heavy infiltration of CD8 + T cells and an infiltration pattern that resembles ulcerative colitis. Virchows Arch 479(6):1119–1129. https://doi.org/10.1007/s00428-021-03170-x
doi: 10.1007/s00428-021-03170-x
pubmed: 34338882
pmcid: 8724151
Dougan M (2023) Weighing antitumor immunity against life-threatening myocarditis from immune-checkpoint inhibitors. Cancer Discov 13(5):1040–1042. https://doi.org/10.1158/2159-8290.CD-23-0199
doi: 10.1158/2159-8290.CD-23-0199
pubmed: 37139724
Suresh K, Naidoo J, Zhong Q, Xiong Y, Mammen J, de Flores MV, Cappelli L, Balaji A, Palmer T, Forde PM et al (2019) The alveolar immune cell landscape is dysregulated in checkpoint inhibitor pneumonitis. J Clin Investig 129(10):4305–4315. https://doi.org/10.1172/JCI128654
doi: 10.1172/JCI128654
pubmed: 31310589
pmcid: 6763233
Suzuki K, Yanagihara T, Matsumoto K, Kusaba H, Yamauchi T, Ikematsu Y, Tanaka K, Otsubo K, Inoue H, Yoneshima Y et al (2020) Immune-checkpoint profiles for T cells in bronchoalveolar lavage fluid of patients with immune-checkpoint inhibitor-related interstitial lung disease. Int Immunol 32(8):547–557. https://doi.org/10.1093/intimm/dxaa022
doi: 10.1093/intimm/dxaa022
pubmed: 32253426
Larsen BT, Chae JM, Dixit AS, Hartman TE, Peikert T, Roden AC (2019) Clinical and histopathologic features of immune checkpoint inhibitor-related pneumonitis. Am J Surg Pathol 43(10):1331–1340. https://doi.org/10.1097/PAS.0000000000001298
doi: 10.1097/PAS.0000000000001298
pubmed: 31162288
Meyer KC, Raghu G (2011) Bronchoalveolar lavage for the evaluation of interstitial lung disease: is it clinically useful? Eur Respir J 38(4):761–769. https://doi.org/10.1183/09031936.00069509
doi: 10.1183/09031936.00069509
pubmed: 21540304
Gharsalli H, Mlika M, Sahnoun I, Maalej S, Douik El Gharbi L, Mezni FE (2018) The utility of bronchoalveolar lavage in the evaluation of interstitial lung diseases: a clinicopathological perspective. Semin Diagn Pathol 35(5):280–287. https://doi.org/10.1053/j.semdp.2018.08.003
doi: 10.1053/j.semdp.2018.08.003
pubmed: 30173880
Sun Y, Shao C, Li S, Xu Y, Xu K, Zhang Y, Huang H, Wang M, Xu Z (2020) Programmed cell death 1 (PD-1)/PD-ligand 1(PD-L1) inhibitors-related pneumonitis in patients with advanced non-small cell lung cancer. Asia Pac J Clin Oncol 16(6):299–304. https://doi.org/10.1111/ajco.13380
doi: 10.1111/ajco.13380
pubmed: 32757454
pmcid: 7754394
Travis WD, Costabel U, Hansell DM, King TE Jr, Lynch DA, Nicholson AG, Ryerson CJ, Ryu JH, Selman M, Wells AU et al (2013) An official American thoracic society/European respiratory society statement: update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. Am J Respir Crit Care Med 188(6):733–748. https://doi.org/10.1164/rccm.201308-1483ST
doi: 10.1164/rccm.201308-1483ST
pubmed: 24032382
pmcid: 5803655
National Institutes of Health, National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE) v 5.0 2017. Available from: https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_5x7.pdf .
Meyer KC, Raghu G, Baughman RP, Brown KK, Costabel U, du Bois RM, Drent M, Haslam PL, Kim DS, Nagai S et al (2012) An official American thoracic society clinical practice guideline: the clinical utility of bronchoalveolar lavage cellular analysis in interstitial lung disease. Am J Respir Crit Care Med 185(9):1004–1014. https://doi.org/10.1164/rccm.201202-0320ST
doi: 10.1164/rccm.201202-0320ST
pubmed: 22550210
Hogea SP, Tudorache E, Pescaru C, Marc M, Oancea C (2020) Bronchoalveolar lavage: role in the evaluation of pulmonary interstitial disease. Expert Rev Respir Med 14(11):1117–1130. https://doi.org/10.1080/17476348.2020.1806063
doi: 10.1080/17476348.2020.1806063
pubmed: 32847429
Kowalski B, Valaperti A, Bezel P, Steiner UC, Scholtze D, Wieser S, Vonow-Eisenring M, Widmer A, Kohler M, Franzen D (2022) Analysis of cytokines in serum and bronchoalveolar lavage fluid in patients with immune-checkpoint inhibitor-associated pneumonitis: a cross-sectional case-control study. J Cancer Res Clin Oncol 148(7):1711–1720. https://doi.org/10.1007/s00432-021-03750-z
doi: 10.1007/s00432-021-03750-z
pubmed: 34347128
Meyer KC, Soergel P (1999) Variation of bronchoalveolar lymphocyte phenotypes with age in the physiologically normal human lung. Thorax 54(8):697–700. https://doi.org/10.1136/thx.54.8.697
doi: 10.1136/thx.54.8.697
pubmed: 10413722
pmcid: 1745554
Danila E, Norkuniene J, Jurgauskiene L, Malickaite R (2009) Diagnostic role of BAL fluid CD4/CD8 ratio in different radiographic and clinical forms of pulmonary sarcoidosis. Clin Respir J 3(4):214–221. https://doi.org/10.1111/j.1752-699X.2008.00126.x
doi: 10.1111/j.1752-699X.2008.00126.x
pubmed: 20298407
Reschke R, Shapiro JW, Yu J, Rouhani SJ, Olson DJ, Zha Y, Gajewski TF (2022) Checkpoint blockade-induced dermatitis and colitis are dominated by tissue-resident memory T Cells and Th1/Tc1 cytokines. Cancer Immunol Res 10(10):1167–1174. https://doi.org/10.1158/2326-6066.CIR-22-0362
doi: 10.1158/2326-6066.CIR-22-0362
pubmed: 35977003
pmcid: 9530647
Assarzadegan N, Montgomery E, Anders RA (2018) Immune checkpoint inhibitor colitis: the flip side of the wonder drugs. Virchows Arch 472(1):125–133. https://doi.org/10.1007/s00428-017-2267-z
doi: 10.1007/s00428-017-2267-z
pubmed: 29143108
Pardoll DM (2012) The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 12(4):252–264. https://doi.org/10.1038/nrc3239
doi: 10.1038/nrc3239
pubmed: 22437870
pmcid: 4856023
Sade-Feldman M, Yizhak K, Bjorgaard SL, Ray JP, de Boer CG, Jenkins RW, Lieb DJ, Chen JH, Frederick DT, Barzily-Rokni M et al (2018) Defining T cell states associated with response to checkpoint immunotherapy in melanoma. Cell 175(4):998-1013 e1020. https://doi.org/10.1016/j.cell.2018.10.038
doi: 10.1016/j.cell.2018.10.038
pubmed: 30388456
pmcid: 6641984
Lin X, Deng J, Deng H, Yang Y, Sun N, Zhou M, Qin Y, Xie X, Li S, Zhong N et al (2021) Comprehensive analysis of the immune microenvironment in checkpoint inhibitor pneumonitis. Front Immunol 12:818492. https://doi.org/10.3389/fimmu.2021.818492
doi: 10.3389/fimmu.2021.818492
pubmed: 35095920
Williams KC, Gault A, Anderson AE, Stewart CJ, Lamb CA, Speight RA, Rajan N, Plummer R, Pratt AG (2023) Immune-related adverse events in checkpoint blockade: observations from human tissue and therapeutic considerations. Front Immunol 14:1122430. https://doi.org/10.3389/fimmu.2023.1122430
doi: 10.3389/fimmu.2023.1122430
pubmed: 36776862
pmcid: 9909476
Wang YN, Lou DF, Li DY, Jiang W, Dong JY, Gao W, Chen HC (2020) Elevated levels of IL-17A and IL-35 in plasma and bronchoalveolar lavage fluid are associated with checkpoint inhibitor pneumonitis in patients with non-small cell lung cancer. Oncol Lett 20(1):611–622. https://doi.org/10.3892/ol.2020.11618
doi: 10.3892/ol.2020.11618
pubmed: 32565986
pmcid: 7285943
Kimura A, Kishimoto T (2010) IL-6: regulator of Treg/Th17 balance. Eur J Immunol 40(7):1830–1835. https://doi.org/10.1002/eji.201040391
doi: 10.1002/eji.201040391
pubmed: 20583029
Kishimoto T, Kang S (2022) IL-6 Revisited: from rheumatoid arthritis to CAR T cell therapy and COVID-19. Annu Rev Immunol 40:323–348. https://doi.org/10.1146/annurev-immunol-101220-023458
doi: 10.1146/annurev-immunol-101220-023458
pubmed: 35113729
Laino AS, Woods D, Vassallo M, Qian X, Tang H, Wind-Rotolo M, Weber J (2020) Serum interleukin-6 and C-reactive protein are associated with survival in melanoma patients receiving immune checkpoint inhibition. J Immunother Cancer 8(1):e000842. https://doi.org/10.1136/jitc-2020-000842
doi: 10.1136/jitc-2020-000842
pubmed: 32581042
pmcid: 7312339
Mallardo D, Simeone E, Festino L, Tuffanelli M, Vanella V, Trojaniello C, Vitale MG, Ottaviano M, Capone M, Madonna G et al (2023) IL-6 as new prognostic factor in patients with advanced cutaneous squamous cell carcinoma treated with cemiplimab. J Transl Med 21(1):140. https://doi.org/10.1186/s12967-023-03971-5
doi: 10.1186/s12967-023-03971-5
pubmed: 36823670
pmcid: 9948392
Soler MF, Abaurrea A, Azcoaga P, Araujo AM, Caffarel MM (2023) New perspectives in cancer immunotherapy: targeting IL-6 cytokine family. J Immunother Cancer 11(11):e007530. https://doi.org/10.1136/jitc-2023-007530
doi: 10.1136/jitc-2023-007530
pubmed: 37945321
pmcid: 10649711
Fa’ak F, Buni M, Falohun A, Lu H, Song J, Johnson DH, Zobniw CM, Trinh VA, Awiwi MO, Tahon NH et al (2023) Selective immune suppression using interleukin-6 receptor inhibitors for management of immune-related adverse events. J Immunother Cancer 11(6):e006814. https://doi.org/10.1136/jitc-2023-006814
doi: 10.1136/jitc-2023-006814
pubmed: 37328287
pmcid: 10277540
Si X, Zheng X, Tian X, Wang H, Xu Y, Zhao J, Chen M, Zhong W, Wang M, Zhang L et al (2023) Analysis of cytokines in bronchoalveolar lavage fluid in patients with checkpoint inhibitor pneumonitis and pulmonary infection: a case-control study. Thorac Cancer 14(21):2038–2044. https://doi.org/10.1111/1759-7714.14987
doi: 10.1111/1759-7714.14987
pubmed: 37259819
pmcid: 10363818
Picca A, Valyraki N, Birzu C, Kramkimel N, Hermine O, Zahr N, Berzero G, Psimaras D (2021) Anti-interleukin-6 and Janus kinase inhibitors for severe neurologic toxicity of checkpoint inhibitors. Neurol Neuroimmunol Neuroinflamm. https://doi.org/10.1212/NXI.0000000000001073
doi: 10.1212/NXI.0000000000001073
pubmed: 34497101
pmcid: 8439960
Tanaka Y, Luo Y, O’Shea JJ, Nakayamada S (2022) Janus kinase-targeting therapies in rheumatology: a mechanisms-based approach. Nat Rev Rheumatol 18(3):133–145. https://doi.org/10.1038/s41584-021-00726-8
doi: 10.1038/s41584-021-00726-8
pubmed: 34987201
pmcid: 8730299